AB Science’s Masitinib MS Trial Update: What Suspended Phase 3 Activity Means for Investors

Ab Science (ABSCF) announced an update on their ongoing clinical study.

AB Science (ABSCF) is running a late-stage study of masitinib in progressive multiple sclerosis, a severe form of the disease with limited options. The trial, officially titled “A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study…,” aims to test whether masitinib can slow disability while keeping side effects in check.

The treatment is an oral drug called masitinib, also known as AB1010, taken twice a day. It is designed to block specific cell signals that drive inflammation and nerve damage, offering a potential new option for patients with few effective therapies.

Patients are randomly assigned to masitinib or a matching placebo, with neither they nor their doctors knowing who gets what. This double-blind, placebo-controlled Phase 3 design is the standard for testing if a drug really works and is safe, with the main goal focused on treatment benefit.

The study runs for 96 weeks of treatment, so results take time to mature. Key history points include initial submission in late June 2022 and a fresh update posted 04 May 2026, signaling ongoing regulatory and operational activity despite the current “suspended” status.

For investors, the latest update keeps masitinib on the radar in a tough part of the multiple sclerosis market, where large players like Biogen and Roche are also active. Any clear path to restarting or completing this Phase 3 trial could swing AB Science’s valuation sharply, as success would support a first-in-class, high-need indication.

The study remains listed as suspended but actively updated, with further details available on the ClinicalTrials.gov portal under identifier NCT05441488.

To learn more about ABSCF’s potential, visit the Ab Science drug pipeline page.